Napabucasin ( BBI-608 )
Cancer Stemness Inhibitor

For metastatic patients there is a helpful development. The cancer stemness inhibitor Napabucasin (BBI-60 performed favorably in a Phase 1b/2 clinical trial when combined with gemcitabine (gem) and nab-paclitaxel (nabPTX)
Among 66 (Intent To Treat) patients, the Disease Control Rate was 77% (51 patients), with 2 Complete Responses (3%) and 28 Partial Responses (42%).
Maturing median progression free survival and overall survival (OS) in ITT pts was >7.1 and >10.7 months, respectively. A Complete Response (absence of disease) is a very usual and welcome event.